-
Quest Diagnostics is selling a blood test online to consumers. But results may not be reliable or easy to interpret. And it isn’t covered by insurance.
-
Under the bill, the Florida Department of Law Enforcement would develop the training in conjunction with the Department of Elder Affairs.
-
On WGCU's "Gulf Coast Life," we talk to Jennifer O’Brien, a USF associate professor of psychology and one of the lead investigators in the Active Mind study.
-
Treatments that can slow the disease in some patients have recently become more widely available, but not everyone can benefit.
-
Connie Storms, with the Alzheimer's Association, says Hispanics in the U.S. are 1½ times more likely to develop Alzheimer's than non-Hispanic whites. The PSA campaign promotes early detection.
-
From Phoenix to Kansas City, airports have added special lanyards, a quiet room and even a simulation center where caretakers and those with dementia can learn about flying. But most large U.S. airports are behind the curve.
-
Particle pollution from sugar cane burning can cross the blood brain barrier and lead to brain inflammation.
-
Insurers selling coverage in North Carolina, Pennsylvania and New York, among other states, say they won’t cover Leqembi with insurance offered on the individual market and through employers because they see the $26,000-a-year drug as experimental.
-
Clinics serving Alzheimer’s patients are working out the details of who will get treated with the new drug Leqembi. It won’t be for everyone with memory-loss symptoms.
-
The annual cost of lecanemab treatment quadruples if the expense of brain scans to monitor for bleeds and other associated care is factored in. The full financial toll likely puts it beyond reach for low-income seniors.